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Abstract Interleukin-15 (IL-15) is a pro-in£ammatory cyto-
kine known as a general inhibitor of apoptosis, which possesses
potential therapeutic properties. Although IL-15 was previously
found to be a human neutrophil agonist, its mode of action
remains unknown. Herein, we were interested in elucidating
the mechanisms by which it delays neutrophil apoptosis. IL-15
was found to induce tyrosine phosphorylation events and to
prevent loss of the anti-apoptotic Mcl-1 protein expression. Us-
ing di¡erent signal transduction inhibitors, we found that Janus
kinase (Jak)-2, Jak-3, p38 mitogen-activated protein kinase
(MAPK) and extracellular signal-regulated kinase (ERK), but
not G proteins, are involved in IL-15-induced suppression of
apoptosis. Furthermore, we found that IL-15 activates Jak-2,
p38 MAPK and ERK-1/2, but, unlike granulocyte macrophage-
colony-stimulating factor (GM-CSF), it does not activate signal
transducer and activator of transcription (STAT)-5a/b. We con-
clude that IL-15 delays neutrophil apoptosis via several path-
ways, and that Mcl-1 and several kinases contribute to this. We
also conclude that, unlike GM-CSF, IL-15 does not activate the
Jak-2/STAT-5 pathway found to be important in neutrophil
signaling.
6 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Interleukin-15 (IL-15) is a cytokine known to mediate its
biological activity by binding to a speci¢c cell surface receptor
(IL-15R), inducing phosphorylation events in immune cells
such as B and T lymphocytes, NK cells, and other non-im-
mune cells such as the human intestinal epithelial cell line
Caco-2 [1^4]. Information on phosphorylation events medi-
ated by IL-15 is presently lacking for human neutrophils.
The IL-15R is composed of at least three subunits, named
Qc (CD132), IL-2RL (CD122), and the more recently identi¢ed
IL-15RK [5]. The Qc chain is shared by other receptors such as
IL-2R, IL-4R, IL-7R, IL-9R and IL-21R [6^9]. In addition to
the Qc chain, both the IL-2R and IL-15R share the IL-2RL
subunit. This may explain why these two cytokines possess
some redundant biological actions [3,10]. IL-15 is known to
utilize the Janus kinase-signal transducer and activator of
transcription (Jak-STAT) pathway to mediate its e¡ects [3].
Although there are few reports in the literature dealing with
the role of the Jak-STAT pathway in neutrophils, Jak-2 ap-
pears to be preferentially involved in these cells [11^13]. IL-15
is known to recruit Jak-1/3 and STAT-3/5 in immune cells
[6,10,11]. However, this has not been studied in human neu-
trophils. We have previously documented that IL-15 is a neu-
trophil agonist [14]. This cytokine induces RNA synthesis, de
novo protein synthesis, phagocytosis, and delays apoptosis.
More recently, IL-15, unlike IL-2, was found to induce the
production of the potent neutrophil chemoattractant IL-8 and
activation of NF-UB [15]. In addition, it has been reported
that IL-15 could not inhibit the ability of the plant lectin
Viscum album agglutinin-I (VAA-I) to induce neutrophil apo-
ptosis, and this was correlated with an inhibition of de novo
protein synthesis induced by VAA-I [16].
The di¡erential e¡ects of IL-15 and IL-2 on human neutro-
phils can be explained by the fact that these cells express a
high a⁄nity IL-15R (Qc, IL-2RL, and IL-15RK) whereas they
express an IL-2R of intermediate a⁄nity, which is lacking one
component, namely, the IL-2RK (CD25) [17^19].
IL-15 is well recognized for its ability to delay apoptosis
[14,20^24]. However, the mechanisms involved in this process
have not been studied. In ¢broblasts, it was recently demon-
strated that IL-15 inhibits TNF-K-induced apoptosis by
TRAF2 (TNFR associated factor 2) recruitment to the IL-
15RK chain [25]. Maintenance of the anti-apoptotic Bcl-2 pro-
tein expression by IL-15 was previously demonstrated to pro-
mote NK cell survival [26]. The manner in which IL-15 delays
human neutrophil apoptosis is currently unknown. It is of
great importance to elucidate how IL-15 delays apoptosis,
since this cytokine possesses potent pro-in£ammatory activ-
ities and interesting potential therapeutic properties for hu-
mans, especially in advanced cancers [27^29].
Neutrophils are terminally non-dividing mature cells known
to spontaneously undergo apoptosis without any apparent
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stimulation. Because of their importance in the in£ammatory
process and because of their high cell turnover rate, an in-
creasing number of studies have focused on the cellular and
molecular biology of neutrophil apoptosis [30^32]. Pharmaco-
logical manipulation of neutrophil apoptosis is certainly of
great importance for developing potential therapeutic strat-
egies [30,31].
Among the di¡erent mechanisms involved in the regulation
of neutrophil apoptosis, members of the Bcl-2 family proteins
were found to exert pivotal roles. Certain members of this
family act by protecting from apoptosis (Bcl-XL and Mcl-1,
Bcl-2 being absent in mature neutrophils), while others pro-
mote apoptosis (Bad, Bak, Bax, Bid) [33]. Recently, Mcl-1 has
gained attention for its role in the neutrophil apoptotic rate
[32^34], since it was found to be freely expressed in the cytosol
and to be rapidly induced by di¡erent factors that delay neu-
trophil apoptosis (granulocyte macrophage-colony-stimulating
factor (GM-CSF), sodium butyrate, IL-1L, and lipopolysac-
charide (LPS)), while its loss during normal aging or hypoxia
was found to promote apoptosis. The role of Mcl-1 in IL-15-
induced suppression of neutrophil apoptosis is presently un-
known.
The present study was conducted in order to better under-
stand the mechanism by which IL-15 delays human neutrophil
apoptosis. We found that this cytokine induces tyrosine phos-
phorylation events in neutrophils and that two important pro-
teins involved in IL-15-induced suppression of neutrophil ap-
optosis are Jak-2 and p38 mitogen-activated protein kinase
(MAPK). IL-15 was also found to prevent the loss of anti-
apoptotic Mcl-1 protein expression.
2. Materials and methods
2.1. Chemicals and agonists
The plant lectin VAA-I derived from V. album was purchased from
Sigma Chemical Company (St. Louis, MO, USA). The protein tyro-
sine kinase inhibitor genistein and the Jak-3 speci¢c inhibitor I were
purchased from Calbiochem (La Jolla, CA, USA). The Jak-2/Jak-3
STAT-1, -3, -5a, and -5b inhibitor tyrphostin B42 (or AG490), the
MEK inhibitor PD098059, the p38 MAPK inhibitor SB203580, and
the G protein inhibitor Pertussis toxin were purchased from Sigma.
IL-15 was obtained from PeproTech Inc. (Rocky Hill, NJ, USA).
2.2. Neutrophil isolation
Cells were isolated from venous blood of healthy volunteers by
dextran sedimentation followed by centrifugation over Ficoll-Hypa-
que (Pharmacia Biotech Inc, QC, Canada), as previously described
[14,16^18]. Blood donations were obtained from informed and con-
senting individuals according to our institutionally approved proce-
dures. Cell viability (s 98%) was monitored by trypan blue exclusion
and the purity (s 98%) was veri¢ed by cytology from cytocentrifuged
preparations colored by Di¡-Quick staining [14,16,17].
2.3. Phosphorylation events
Neutrophils (40U106 cells/ml in RPMI-1640) were incubated for 1,
5, 15, or 30 min at 37‡C with bu¡er alone, with 65 ng/ml GM-CSF, or
with 250 ng/ml IL-15 in a ¢nal volume of 120 Wl. Reactions were
stopped by adding 125 Wl of 2ULaemmli’s sample bu¡er as we
have described elsewhere [16,35,36]. Aliquots corresponding to
1U106 cells were loaded onto 10% sodium dodecyl sulfate^polyacryl-
amide gel electrophoresis (SDS^PAGE) and transferred from gel to
polyvinylidene di£uoride (PVDF) membranes (Millipore, Bedford,
MA, USA). Non-speci¢c sites were blocked with 1% bovine serum
albumin (BSA) in Tris-bu¡ered saline (TBS)-Tween (25 mM Tris^
HCl, pH 7.8, 190 mM NaCl, 0.15% Tween-20) for 1 h at room tem-
perature. After washing, the membranes were incubated with mono-
clonal anti-phosphotyrosine UB 05-321 (1:4000) (UBI) for 1 h at
room temperature. Membranes were then washed and incubated
with a horseradish peroxidase-conjugated goat anti-mouse IgG+IgM
(1:10 000) (Jackson Immunoresearch Laboratories, Inc.) for 1 h at
room temperature in fresh blocking solution. Membranes were
washed three times with TBS-Tween, and phosphorylated bands
were revealed with the enhanced chemiluminescence (ECL) Western
blotting detection system (Amersham, Pharmacia Biotech Inc). Pro-
tein loading was veri¢ed by staining the membranes with Coomassie
blue at the end of the experiments.
2.4. Assessment of neutrophil apoptosis
Freshly isolated human neutrophils (10U106 cells/ml in RPMI-1640
supplemented with 10% autologous serum) were pre-incubated for 60
min in 24-well plates with the transduction signal inhibitors and then
incubated for 23 h in the presence or absence of IL-15. Inhibitors
remained in the culture. Apoptosis was evaluated by cytology as pre-
viously published [14,16]. Brie£y, cytocentrifuged preparations of neu-
trophils (withV200 Wl) were performed using a Cyto-tek0 centrifuge
(Miles Scienti¢c, IN, USA) and processed essentially as previously
documented [14,16]. Cells were examined by light microscopy at
400U ¢nal magni¢cation and apoptotic neutrophils were de¢ned as
cells containing one or more characteristic darkly stained pycnotic
nuclei. An ocular containing a 10U10 squares grill was used in order
to count at least ¢ve di¡erent ¢elds (s 100 cells) for the assessment of
apoptotic cells. Results were expressed as percentage of apoptotic
cells. This assay was found to correlate well with other techniques
such as £uorescein isothiocyanate (FITC)-annexin-V/PI binding [16],
cell surface CD16 expression [37], and PI/Hoechst binding [14]. In the
present study, we have con¢rmed the apoptotic rate of neutrophils by
£ow cytometry and observed that the percentage of FITC-annexin-V
positive cells was signi¢cantly diminished in cells treated with GM-
CSF (39.1U 4.9) or IL-15 (30.3 U 7), when compared to untreated cells
(67.2U 3.7) (meanUS.E.M., n=3) (not shown).
2.5. Mcl-1 expression
Neutrophils (10U106 cells/ml RPMI-HEPES-P/S) were stimulated
24 h with or without agonists and were harvested and washed twice
with cold phosphate-bu¡ered saline (PBS). Whole cell lysates were
prepared as above. Proteins (1U106 cells/well) were separated on
10% SDS^polyacrylamide gels and transferred to nitrocellulose. Mem-
branes were blocked overnight at 4‡C in TBS-Tween+3% non-fat dry
milk (Carnation, Don Mills, ON, Canada). After washing, the Mcl-1
antibody (K-20 clone from Santa Cruz Biotechnology) was added at a
¢nal dilution of 1:200 in TBS-Tween+3% non-fat dry milk for 1 h at
room temperature. Membranes were then washed with TBS-Tween
and incubated for 1 h at room temperature with a goat anti-rabbit
horseradish peroxidase (HRP) secondary antibody (Jackson Immuno-
research Laboratories) at 1:20 000 in TBS-Tween+3% non-fat dry
milk followed by washes. The Mcl-1 protein was revealed with ECL
and quanti¢ed using a Fluor-S MultiImager (Bio-Rad) and the Multi-
Analyst version 1.1 program (Bio-Rad).
2.6. Jak-2, p38, extracellular signal-regulated kinase (ERK)-1/2 and
STAT-5a/b phosphorylations
This was performed essentially as described above for the Mcl-1
expression except that a rabbit polyclonal anti-Jak-2[pYpY1007=1008]
(BioSource international, Camarillo, CA, USA), anti-p38[pTpY180=182]
(BioSource), anti-pERK-1/2 MAPK (BioSource) or anti-STAT-5a/b
(Y694/Y699, Upstate Biotechnology, Lake Placid, NY, USA) phos-
phospeci¢c antibody was used for the primary antibody incubation at
a concentration of 0.5 Wg/ml. Phosphorylated proteins were revealed
with ECL and quanti¢ed using a Fluor-S MultiImager as above. In
some experiments, speci¢c antibodies against the non-phosphorylated
form of ERK-1/2 (UBI) and STAT-5b (UBI) were used.
3. Results
3.1. IL-15 prevents the loss of neutrophil Mcl-1 expression
We have previously documented that IL-15 induces sup-
pression of human neutrophil apoptosis [14] and that it can-
not inhibit VAA-I-induced apoptosis [16]. Mcl-1 was recently
found to be a key element in the regulation of human neu-
trophil apoptosis [32^34]. As illustrated in Fig. 1, in contrast
to spontaneous and to VAA-I-induced neutrophil apoptosis,
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IL-15 was found to prevent the loss of Mcl-1 expression,
previously detected as a doublet of 40/42 kDa or infrequently
as a single band [33,34]. As expected, GM-CSF was found to
prevent the loss of Mcl-1 [33,34] when compared to neutro-
phils undergoing spontaneous apoptosis.
3.2. Involvement of tyrosine kinases in IL-15-induced
suppression of neutrophil apoptosis
Tyrosine kinases were previously found to be involved in
suppressing granulocyte apoptosis [38,39]. In order to eluci-
date the mechanisms of IL-15-induced suppression of human
neutrophil apoptosis, we investigated the role of di¡erent ki-
nases by using several inhibitors. As illustrated in Fig. 2, the
pan tyrosine kinase inhibitor, genistein, was found to inhibit
the e¡ect of IL-15 by 84%. The more speci¢c tyrosine kinase
inhibitor AG490 (Jak-2/Jak-3 STAT-1, -3, -5a, and -5b STAT
inhibitor), the Jak-3 speci¢c inhibitor I, and the serine/threo-
nine p38 MAPK inhibitor SB203580 and the MEK inhibitor
PD098059, were found to inhibit this response by 100, 49, 41,
and 79%, respectively. The G protein inhibitor P. toxin did
not alter the IL-15-induced suppression of apoptosis. These
results indicate that IL-15 induces suppression of neutrophil
apoptosis via di¡erent kinases; in particular, Jak proteins ap-
pear to play a major role.
3.3. IL-15 induces phosphorylation events in human neutrophils
As illustrated in Fig. 3, IL-15 was found to induce tyrosine
phosphorylation events in human neutrophils. Note that we
have performed time-course experiment studies (1, 5, 15, 30,
and 60 min), but only the results obtained after 1 min are
shown for simplicity and also because the response was largely
attenuated after 30 min. In two separate experiments, we also
found that VAA-I could not alter the IL-15-induced tyrosine
phosphorylation events (data not shown). This is not without
precedent, as we have recently demonstrated that VAA-I
could not alter GM-CSF-induced tyrosine phosphorylation
in human neutrophils [16]. A particular protein with a Mr
of V120 kDa (near the molecular weight of Jaks) exhibited
tyrosine phosphorylation after IL-15 stimulation.
3.4. IL-15 activates Jak-2
Based on these latter results, and because Jak-2 is known to
be an important tyrosine kinase involved in general neutrophil
cell physiology [11^13,38], we then decided to verify whether
or not IL-15 can activate Jak-2. As illustrated in Fig. 4, IL-15
can rapidly induce tyrosine phosphorylation of Jak-2 and this
was reversed by addition of genistein or the Jak-2/Jak-3 in-
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Fig. 1. Loss of neutrophil Mcl-1 expression is prevented by IL-15
but not by VAA-I. Neutrophils were incubated in the presence of
agonists for 22 h and the level of expression of the anti-apoptotic
p40/42 Mcl-1 protein was detected by immunoblotting as described
in Section 2. A: Results are from one representative experiment out
of four. Note that Mcl-1 is down-regulated in untreated 22 h aged
neutrophils (Ctrl) when compared to freshly isolated cells (Fresh)
and that results obtained with other treatments should be compared
to lane 2 (Ctrl) and not lane 1 (Fresh). The second band is prob-
ably a degradation product, as sometimes observed by other investi-
gators using the same anti-Mcl-1 antibody [33,34]. B: The ¢gure
represents the densitometric analysis of Mcl-1 protein (n=4).
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Fig. 2. Involvement of tyrosine kinases in IL-15-induced suppression
of human neutrophil apoptosis. Neutrophils (10U106 cells/ml) were
treated for 1 h in the presence or absence of inhibitors (inh) prior
to an incubation of 23 h in RPMI-1640 supplemented with 10% au-
tologous serum in the presence or absence of IL-15. Apoptosis was
assessed by cytology from cytocentrifuged preparations stained with
Di¡-Quick as described in Section 2. Results are meansUS.E.M.
(nv 3). Dil, the diluent (6 1% dimethyl sulfoxide (DMSO) in the ¢-
nal volume) was used to solubilize all inhibitors except P. toxin,
which was solubilized in water before being diluted with the bu¡er.
The concentration of inhibitor was: 50 Wg/ml for genistein; 100 WM
for AG490; 100 Wg/ml for Jak-3 inhibitor I; 50 ng/ml for P. toxin ;
1 WM for SB203580; and 10 WM for PD098059.
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hibitor AG490. As expected, Jak-2 was activated by GM-CSF
[11,12]. Note that, as reported by the manufacturer, we de-
tected a few bands that may correspond to degradation prod-
ucts of Jak-2.
3.5. Activation of p38 by IL-15
The role of p38 MAPK in neutrophil apoptosis is obscure
and varied according to di¡erent laboratory conditions [40^
42]. Here, we were interested in answering whether or not p38
MAPK is activated by IL-15, since we have found that pre-
treatment with SB203580 inhibits the e¡ect of IL-15 (Fig. 2).
As illustrated in Fig. 5, IL-15, as well as GM-CSF, was found
to activate p38 MAPK. Although we have performed time-
course experiments, only the results obtained after 15 min are
shown.
3.6. IL-15 induces phosphorylation of ERK-1/2
According to our results (Fig. 2) and knowing that IL-15
was recently found to mediate its biological activity partly via
the MAPK ERK-1 pathway in human U937 leukemia cells
[43], we decided to investigate the role of ERK-1/2 in IL-15-
induced neutrophils. As illustrated in Fig. 6, as GM-CSF, IL-
15 was found to induce phosphorylation of ERK-1/2.
3.7. Role of STAT-5 in IL-15-induced human neutrophils
STAT-5 is an important transcription factor in human neu-
trophils. In particular, GM-CSF was found to activate STAT-
5 in these cells [12]. We then decided to study the role of
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Fig. 4. IL-15 induces Jak-2 phosphorylation in human neutrophils. Cells were freshly isolated as described in Section 2 and were pre-incubated
30 min with or without inhibitors (50 Wg/ml for genistein or 200 WM for AG490) before being stimulated for 1 min with bu¡er (lane 1), 65 ng/
ml GM-CSF (lane 2), or 250 ng/ml IL-15 (lane 3). Upper panel: The membrane was revealed with an anti-phosphorylated Jak-2 (p-Jak-2) anti-
body as described in Section 2. Bottom panel: Representation of the corresponding Coomassie blue-stained membrane indicating equivalent
loading. Numbers on the left are molecular weight standards that were loaded in the fourth lane (mw). Results shown are from one experiment
and are representative of those obtained from three experiments. The relative intensity of phosphorylated Jak-2 following treatment with bu¡er
(lane 1), GM-CSF (lane 2) or IL-15 (lane 3) is indicated in the inset (n=3).
Fig. 3. Phosphorylation events in IL-15-induced neutrophils. Freshly
isolated human neutrophils (40U106 cells/ml) were incubated with
or without agonists and cell lysates were prepared before performing
Western blot experiments as described in Section 2. A: Cells were
treated for 1 min with bu¡er (lane 1), 65 ng/ml GM-CSF (lane 2),
or 250 ng/ml IL-15 (lane 3). Results shown are from one experiment
but are representative of those obtained from four experiments, con-
ducted with di¡erent blood donors. The arrow indicates a 120 kDa
region. B: The corresponding membrane was stained with Coomas-
sie blue to verify the protein loading.
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STAT-5 in neutrophils following IL-15 stimulation. As indi-
cated in Fig. 7, IL-15, in contrast to GM-CSF, does not
activate STAT-5. This suggests that IL-15 induces di¡erent
cell signaling events than GM-CSF.
4. Discussion
IL-15 is a pro-in£ammatory cytokine suspected to be an
important pathogenic factor in di¡erent human diseases, in-
cluding immunoin£ammatory disorders [44]. In this regard,
high concentrations of IL-15 have been detected in the syno-
vial £uid and in synovial membrane cells from rheumatoid
patients [1,2,45,46]. In addition, the identi¢cation of IL-15
as a neutrophil agonist [12,13] together with its ability to
enhance the production of TNF-K through activation of syno-
vial T cells and the production of IL-8 by human neutrophils,
support a pathogenic role of IL-15 in in£ammatory disorders.
Moreover, elevated levels of IL-15 have been demonstrated in
peripheral blood mononuclear cells from patients with active
ulcerative colitis and in alveolar macrophages from patients
with active sarcoidosis, and in chronic hepatitis C [47^50].
Binding of IL-15 to its receptor is known to induce tyrosine
phosphorylation in immune cells, as well as in cells of non-
immune origin such as intestinal epithelial Caco-2 cells [4].
Prior to the present study, the e¡ect of IL-15 on tyrosine
phosphorylation events in human neutrophils was unknown.
Our results concur with the fact that human neutrophils ex-
press the complete IL-15R composed of Qc, IL-2RL, and IL-
15RK chains [17^19], since it induces cell signaling. Jak-2 was
recently found to be a candidate involved in GM-CSF-in-
duced suppression of apoptosis by another type of granulo-
cyte, the eosinophil [38]. In this study, we have demonstrated
that, among numerous tyrosine kinases that could be in-
volved, at least Jak-2 has been identi¢ed as contributing to
IL-15-induced suppression of neutrophil apoptosis. To our
knowledge, this is the ¢rst time that Jak-2 activation has
been correlated with a human neutrophil function, namely
apoptosis. Prior to our study, researchers have focused only
on the ability of di¡erent molecules, such as GM-CSF, to
phosphorylate Jak-2 [11^13]. Our experiments conducted
with the panel of inhibitors suggest that IL-15 might utilize
di¡erent cell signaling pathways to mediate its e¡ects on hu-
man neutrophils.
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Fig. 5. IL-15 induces p38 MAPK in human neutrophils. Cells were
freshly isolated as described in Section 2 and were stimulated for 15
min with bu¡er (lane 1), 65 ng/ml GM-CSF (lane 2), or 250 ng/ml
IL-15 (lane 3). A: Upper panel illustrates the membrane that was
revealed with an anti-phosphorylated p38 MAPK antibody as de-
scribed in Section 2 and the bottom panel represents the corre-
sponding Coomassie blue-stained membrane indicating equivalent
loading. Results shown are from one experiment and are representa-
tive of those obtained from three experiments. B: The relative inten-
sity of phosphorylated p38 following treatment with bu¡er (lane 1),
GM-CSF (lane 2) or IL-15 (lane 3) is indicated in the inset (n=3).
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Fig. 6. IL-15 induces the phosphorylation of ERK-1/2 in human
neutrophils. Cells were freshly isolated as described in Section 2 and
were stimulated for 15 min with bu¡er (lane 1), 65 ng/ml GM-CSF
(lane 2), or 250 ng/ml IL-15 (lane 3). Upper panel illustrates the
membrane that was revealed with an anti-phosphorylated ERK-1/2
antibody as described in Section 2 and the bottom panel illustrates
the corresponding membrane stained with the unphosphorylated
form of ERK-1/2 indicating equivalent loading. Results shown are
from one experiment and are representative of those obtained from
three experiments. Numbers in the right are the molecular weight
standards.
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Fig. 7. IL-15 does not activate the phosphorylation of the transcrip-
tion factor STAT-5 in human neutrophils. Cells were freshly iso-
lated as described in Section 2 and were stimulated for 5 min with
bu¡er (lane 1), 65 ng/ml GM-CSF (lane 2), or 250 ng/ml IL-15
(lane 3) or for 15 min (lanes 4^6, in the same order). The upper
panel illustrates the membrane that was revealed with an anti-phos-
phorylated STAT-5a/b antibody as described in Section 2 and the
bottom panel is the corresponding membrane stained with the un-
phosphorylated form of STAT-5b. Note that although the loading
was higher with IL-15 (lane 6) than in control (lane 4) or GM-CSF
(lane 5), the phosphorylated forms of STAT-5a/b were not detected,
indicating that IL-15 does not recruit STAT-5a/b. Results shown
are from one experiment and are representative of those obtained
from four experiments.
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It has been reported that both GM-CSF and anti-Fas anti-
bodies, well known to delay and induce apoptosis respectively,
did not activate p38 MAPK [40]. Others have found that at
least two pathways leading to apoptosis exist in human neu-
trophils, one that is dependent on p38 MAPK activation and
another that is independent of this kinase [42]. In addition to
the Jak-STAT pathway, we found that the p38 MAPK and
ERK-1/2 cascades may be involved in IL-15-induced suppres-
sion of neutrophil apoptosis. As for Jak-2, we have found that
IL-15 activates p38 MAPK. The precise role of Jak-3 (and the
various STATs) requires further investigation, since the spe-
ci¢c Jak-3 inhibitor was also found to reverse IL-15-induced
suppression of neutrophil apoptosis (Fig. 2). This attests to
the complexity of the apoptotic process in these cells. Our
results are in agreement with others demonstrating that, in
human neutrophils, Jak-2 is a pivotal player in cell signaling
[11^13]. Considering that tyrphostin B42 (AG490) is now rec-
ognized as an inhibitor of Jak-2/Jak-3 STAT-1, -3, -5a, and -5b
[51,52], our results agree with the fact that IL-15 utilizes at
least the JAK-STAT pathway to mediate its e¡ect on neutro-
phils. Interestingly, we found that IL-15, unlike GM-CSF,
does not utilize the JAK-2/STAT-5 pathway, since it does
not induce phosphorylation of STAT-5.
We have also found that IL-15 can suppress neutrophil
apoptosis by preventing the loss of Mcl-1 expression. This
loss not only occurs in spontaneous apoptosis, but also during
VAA-I-induced neutrophil apoptosis, as well as during co-in-
cubation with both VAA-I and IL-15 (unpublished data).
Mcl-1 was recently found to be synthesized de novo and
linked to the inhibition of neutrophil apoptosis in human
neutrophils, as demonstrated by the use of antisense oligonu-
cleotides [34]. As previously stated, IL-15 is known to induce
de novo protein synthesis in human neutrophils [14]. Our
present results indicate that IL-15 delays neutrophil apopto-
sis by synthesizing at least Mcl-1 when compared with con-
trol cells incubated for 24 h. This con¢rms the concept that
neutrophils delay their programmed cell death via the syn-
thesis of macromolecules [53]. However, when comparing de
novo protein synthesis of Mcl-1 with the level expressed in
freshly isolated neutrophils, it appears more appropriate to
state that IL-15 delays its degradation. This is in agreement
with the general hypothesis proposing that factors suppress-
ing neutrophil apoptosis increase or maintain Mcl-1 levels
[32].
The results of the present study indicate that IL-15 induces
phosphorylation events in human neutrophils. Knowing the
cascade of events mediated by IL-15 will open new avenues
for the development of potential new therapeutic strategies.
One of these may be to antagonize the e¡ect of IL-15 by using
downstream inhibitors to Jaks or other related molecule(s). In
this regard, the in vivo e¡ects of tyrphostin B42 in acute
lymphoblastic leukemia and experimental allergic encephalo-
myelitis (EAE), were found to reduce the incidence and se-
verity of the disease [54^56]. Knowing how to block IL-15-
induced suppression of neutrophil apoptosis will certainly be
of bene¢t for the resolution of in£ammation.
New approaches directed toward IL-15, its receptor, or its
signaling pathways may be of value in the therapy of various
diseases, including in£ammatory disorders such as rheumatoid
arthritis. Mcl-1, Jak-2, p38 MAPK, ERK-1/2 may now be
considered as important potential candidates involved in IL-
15-induced suppression of apoptosis.
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